Flavonoid Based Antiviral Targets

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a new class of flavonoid-based compounds designed to modulate the activity of the US28 receptor, a G protein-coupled receptor encoded by Human Cytomegalovirus (HCMV) that plays a key role in viral replication and potentially in inflammatory and proliferative diseases. The patented compounds act as inverse agonists or antagonists of US28, reducing its activity and thereby inhibiting virus proliferation and signaling that can lead to disorders such as viral infections (HCMV and HIV), cancers, and certain cardiovascular and inflammatory conditions. These compounds, including lead candidate 11b, exhibit high specificity for US28, strong efficacy, and low toxicity in cellular models.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment or prevention of Human Cytomegalovirus (HCMV) infections, especially in immunocompromised patients (e.g., transplant recipients).
• Adjunctive therapy or preventive measures for Human Immunodeficiency Virus (HIV) infection.
• Potential treatment of other viral infections where related chemokine receptors are involved in viral entry or replication.
• Therapy for certain cancers linked to abnormal MAPK signaling and potential viral involvement, including HCMV-associated tumors.
• Interventions for acute and chronic inflammatory conditions that are modulated via the US28 receptor or analogous pathways.
• Treatment or prevention of cardiovascular diseases that may be promoted by US28 activity.
• Use in combination therapy with existing antiviral, anti-inflammatory, or anticancer drugs to enhance efficacy and reduce dosages.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a novel, targeted mechanism for inhibiting US28 activity—a key pathway in HCMV proliferation and persistence.
• Lead compounds, especially 11b, demonstrate high efficacy (strong inverse agonism) combined with low toxicity and high specificity, minimizing off-target effects.
• Potentially effective in treating both viral infections (like HCMV and HIV) and non-infectious diseases (cancer, cardiovascular, and inflammatory disorders) where US28 or related chemokine receptors are implicated.
• Offers chemical diversity (various analogs and derivatives), enabling optimization for potency, safety, and pharmacokinetic properties.
• Can be formulated into standard pharmaceutical forms for various routes of administration (oral, injectable, topical, etc.).
• May be combined with other therapeutics, allowing for flexible treatment regimens and possible synergistic effects.
• Represents new chemical space for US28 inhibition, beyond existing peptide or small-molecule antagonists, which may overcome current limitations in efficacy or bioavailability.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to novel compounds for modulating US28 receptor activity and methods for their use in preventing or treating US28 receptor-mediated disorders or conditions.